anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Aida

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 3,551
Current window 2,341-2,370
Pages 119
Rows per page 30
Arc: Aidaclear collectionreset all
18 30 60

Arc

2,341-2,370 of 3,551

filter-aware
01
Slide 1
Features a 3D molecular visualization.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Attention1 hit
02
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Attention1 hit
03
The slide uses a split-screen layout to contrast internal R&D with external partnerships, unified by a central 'discovery programmes' stack.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Attention1 hit
04
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
05
Uses a before-after-framing structure to position the company's solution against industry-wide challenges.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
06
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
07
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
08
The slide uses a hub-and-spoke diagram centered on 'Precision Medicine' with six surrounding functional modules.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
25
The slide uses a process flow diagram to illustrate the transition from dose escalation (DL1-DLx) to expansion cohorts for specific indications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
26
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
27
Data cut-off: 18 October 2023. Includes breakdown by age, sex, ECOG status, prior therapy, and tumor type.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
28
Clinical trial safety data summary.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
31
Includes longitudinal line charts for blood mRNA levels and a bar chart/enrichment plot for tumor response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a split-layout: left side for clinical data results, right side for strategic opportunity/implications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
33
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
34
Includes a waterfall plot showing p53WT cell dependency on MDM2 and a biological process diagram of the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
36
Comparison of protein levels and tumor volume over time across multiple dosing regimens.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
37
The slide uses a standard clinical trial dose-escalation diagram and a demographic table.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
39
The chart is a swimmer plot, a standard tool in oncology clinical trials to visualize duration of response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
40
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
41
The slide uses a split-layout comparing technical mechanism/data (left) with strategic opportunity (right).Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
42
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
43
This is a standard closing slide for an investor presentation.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
44
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
45
The table displays patient counts and percentages for specific adverse events categorized by dose level (DL1-DL5) and overall.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit